Real-Life Use of Posaconazole in Clinical Practice for Onco-Hematological Children: A National Survey by AIEOP Infectious Diseases Working Group
Authors:
- Lorenzo ChiusaroliLCLorenzo Chiusaroli
- Manuela SpadeaMSManuela Spadea
- Cecilia LiberatiCLCecilia Liberati
- Maria Grazia PetrisMPMaria Grazia Petris
- Antonio GrassoAGAntonio Grasso
- Francesco BaccelliFBFrancesco Baccelli
- Maria Vittoria MichelettiMMMaria Vittoria Micheletti
- Pietro GasperiniPGPietro Gasperini
- Maria Rosaria D’amicoMDMaria Rosaria D’amico
- Katia PerruccioKPKatia Perruccio
- Angelica BaroneABAngelica Barone
- Daniela OnofrilloDODaniela Onofrillo
Open Access
- 7 November 2025
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (11) , 797
Abstract
Background: Posaconazole is an antifungal medication used to treat invasive fungal infections (IFI) in pediatric onco-hematological patients. Its approval for pediatric use was recent, and limitations still apply. Despite limited data, the safety and efficacy profile appear generally favorable in children. This study describes how posaconazole is used across centers affiliated with the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP). Methods: A national survey was conducted among physicians within the AIEOP network to evaluate current use of posaconazole in pediatric cancer patients, including those undergoing hematopoietic stem cell transplantation (HSCT). A 25-item web questionnaire was developed and distributed in June 2024. Data analysis involved descriptive statistics. Results: Twenty-one of thirty-one centers (68%) responded, reporting availability of various posaconazole formulations: oral suspension (76%), delayed-release tablets (95%), and intravenous solution (14%). Posaconazole was primarily used for prophylaxis in patients with acute lymphoblastic leukemia (ALL, 38%), acute myeloid leukemia (AML, 38%), and aplastic anemia (19%). It was also used as secondary prophylaxis against previous possible or probable IFI or as salvage therapy for probable or confirmed aspergillosis or mucormycosis, often combined with other treatments. Drug plasma level monitoring was common but varied in scheduling across centers. Most centers (74%) discontinued posaconazole if adverse events suspected drug–drug interactions, such as with vincristine. Conclusions: Posaconazole is widely used in AIEOP centers, though application varies significantly. This variability emphasizes the need for prospective studies to better define indications, dosing, and monitoring protocols for pediatric use of this antifungal.Keywords
This publication has 25 references indexed in Scilit:
- Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemiaJournal of Cancer Research and Clinical Oncology, 2025
- Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)Leukemia, 2025
- Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantationThe Lancet Oncology, 2021
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantationThe Lancet Oncology, 2021
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research ConsortiumThe Lancet Infectious Diseases, 2019
- Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and ChildrenClinical Pharmacokinetics, 2018
- Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropeniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Risk of azole‐enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem – New DilemmaPediatric Blood & Cancer, 2011
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBritish Journal of Clinical Pharmacology, 2003